Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
Vaccine
; 28(18): 3086-94, 2010 Apr 19.
Article
em En
| MEDLINE
| ID: mdl-20199764
ABSTRACT
Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esquemas de Imunização
/
Imunização Secundária
/
Vacinas Pneumocócicas
/
Anticorpos Antibacterianos
Tipo de estudo:
Clinical_trials
Limite:
Child, preschool
/
Humans
/
Infant
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Austrália